Helicobacter pylori (H. pylori) infection is a public concern due to its prevalence, pathogenicity and carcinogenicity. In order to prevent disease onset, it is important to control intragastric H. pylori status. FP-10 is a conjugated caseinate that inhibits bacterial adhesion to gastric mucosa. We determined the effects of FP-10 administration (1.0 g/day, 12 weeks) in asymptomatic H. pylori carriers. Mean ¹³C urea breath test values decreased significantly with FP-10 administration. There were no severe or persistent adverse events during the administration period. Therefore, FP-10 administration is considered to reduce intragastric H. pylori safely and effectively.